Table 3

Secondary endpoints in patients with inflammatory osteoarthritis of the knee who received open-label adalimumab

Baseline

4 weeks

8 weeks

12 weeks^a

22 weeks^b

Patient global

60.6 (22.0)

49.7 (22.1)**

37.4 (22.6)*

36.1 (21.9)*

44.4 (22.5)

Physician global

69.7 (12.7)

44.6 (17.8)*

34.5 (16.9)*

40.7 (22.0)*

40.1 (25.3)

Activity impairment

6.30 (1.17)

5.70 (1.53)

4.90 (1.59)**

5.10 (2.00)*

5.19 (1.80)

Sleep impairment

2.90 (0.64)

2.35 (0.81)

2.10 (0.72)**

2.05 (0.89)**

2.50 (0.73)

Target joint tenderness

1.75 (0.44)

1.00 (0.73)

0.95 (0.69)**

0.95 (0.94)**

0.81 (75)

Target joint swelling

2.15 (0.37)

1.45 (0.89)**

1.00 (1.03)*

1.15 (1.14)**

0.75 (0.77)

Mean (standard deviation) values for secondary endpoints over 22 weeks in 20 patients with inflammatory osteoarthritis of the knee who received open-label adalimumab for 12 weeks. ^aWeek 12 data versus baseline according to paired t test using last-observation-carried-forward data. ^bWeek 22 data are based on 16 patients who attended for assessment. *P < 0.0001, **P < 0.05.

Maksymowych et al. Arthritis Research & Therapy 2012 14:R206   doi:10.1186/ar4044